嵌合抗原受体T细胞治疗结肠癌的研究进展

Research progress of chimeric antigen receptor T cells therapy for colorectal cancer

临床上结肠癌(colorectal cancer,CRC)的治疗方式仍然以手术和化疗为主。但是传统疗法有许多局限性,包括耐药、癌症复发和严重的不良反应。近年来,免疫学在CRC的治疗上取得了重大突破,其中,嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR‐T)疗法表现比较明显。CAR‐T细胞疗法是一种新的基因工程免疫治疗癌症的方法,在治疗肿瘤方面取得了很大的进步。本文将对CAR‐T细胞疗法的优势与局限性、从潜在的CRC治疗靶点到临床前研究和临床试验进行综述。

Currently,the clinical treatment methods for colon cancer are still mainly surgery and chemotherapy.However,the traditional therapies have many limitations,including drug resistance,cancer recurrence and severe adverse reactions.Immunology has made great breakthroughs in the treatment of colon cancer,among which chimeric antigen receptor T cell(CAR-T)therapy is the most significant.CAR-T cell therapy is a new genetically engineered immunotherapy method for cancer,which has made great progress in the treatment of tumors.This paper reviews the advantages and limitations of CAR-T cell therapy,from potential targets for colon cancer treatment to preclinical studies and clinical trials.